Navigation Links
OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Date:2/4/2009

BOTHELL, WA, and VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the two-year survival rate from a Phase 1/2 clinical trial of OGX-011 in combination with first-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). At two years, 30% of patients who had received OGX-011 with first-line chemotherapy were alive. OncoGenex has previously reported a mature median survival of 14.1 months and a one-year survival rate of 54%.

For comparison, published studies using a platinum-based regimen plus gemcitabine as first-line chemotherapy for advanced NSCLC reported median survivals of 8 to 11 months and one-year survival rates of 33% to 43%. Market approval for Avastin plus paclitaxel and carboplatin chemotherapy for NSCLC was based on results showing a median survival of 12.3 months compared to 10.3 months for patients treated with chemotherapy alone. Survival rates for Avastin plus chemotherapy versus chemotherapy alone were reported as 51% versus 44% at one year and 23% versus 15% at two years, respectively.

"The two-year survival rate of 30% in our Phase 1/2 NSCLC study compares favorably to the survival reported for Avastin plus paclitaxel and carboplatin chemotherapy," said Scott Cormack, president and CEO of OncoGenex. "These data remain consistent with our Phase 2 data in prostate cancer suggesting that OGX-011 when added to chemotherapy may improve survival by blocking the production of clusterin, the protein associated with treatment resistance in various cancers."

    Non-Small Cell Lung Cancer Phase 1/2 Study Design with Updated Results as
    of January 23, 2009

This single-arm, open-label study enrolled 81 patients with Stage IIIB (18 percent) or Stage IV (82 percent) NSCLC who were treated with OGX-011 in combination w
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... (PRWEB) June 19, 2013 Bayer CropScience ... first Bayer Bee Care Community Leadership Award. The award ... Congressional Reception in Washington, D.C., an event where ... to the world’s food supply. , The Bayer ... harnessed the power of the honey bee colony to ...
(Date:6/19/2013)... June 19, 2013 ... presents Innovative Drug Delivery Systems: ... Licensing Opportunities for Generic Pharmaceutical ... There are more than ... drugs approved all over the ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Adding ... Pipette.com is now stocked with Simport’s Dropette® and ... aimed at the customer doing basic biology, chemistry and ... and serology). , For over 35 years, Simport has ... plastic labware - products like the Simport Dropette®. Simport’s ...
Breaking Biology Technology:Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2
... (Nasdaq: MNKD ), focused on discovering, developing and,commercializing ... present at the UBS Global Life Sciences Conference on ... Hyatt Hotel in New York, NY. Interested parties ... of the,presentation in the Investor Relations section of the ...
... Sept. 18 InterMune, Inc.,(Nasdaq: ITMN ) today ... other conditions, 3,000,000 shares of its common stock in ... underwriters,a 30-day option to purchase up to an additional ... All of the shares in the offering,will be sold ...
... Sept. 18 /PRNewswire-FirstCall/-- Biodel Inc. (Nasdaq:,BIOD) today ... program,at the 43rd Scientific Sessions of the ... VIAject(TM) Phase II meal study data ... entitled, "Pharmacokinetics and pharmacodynamics of,insulin VIAject(TM), insulin ...
Cached Biology Technology:InterMune Announces Proposed Public Offering of Common Stock 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 3
(Date:6/19/2013)... June 19, 2013 A decade-long JDRF-funded study ... Helmholtz Zentrum Mnchen, Germany, is providing a deeper ... risk of developing type 1 diabetes (T1D), highlighting ... for the disease. The study, "Seroconversion to Multiple ... in Children," was published today in The ...
(Date:6/19/2013)... , June 19, 2013  New York College ... the United States Patent and Trademark Office for detecting ... that reflect whether guards have been injured, attacked or ... extensive portfolio under the Intellectual Properties Agreements of New ... Pamintuan , President of New York ...
(Date:6/19/2013)... Elsevier, a world-leading provider of scientific, technical and ... the launch of a new open access journal, ... GeoResJ , Elsevier,s earth and planetary science journals portfolio ... aims to provide a forum for rapid publication of ... journal will be co-edited by six Executive Editors, each ...
Breaking Biology News(10 mins):New data on islet autoantibodies in young children defines early type 1 diabetes development 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4
... a gene called p63 accelerates aging in mice. Similar versions ... Therefore, the p63 gene is likely to play a fundamental ... p63 gene works, we devised a system for eliminating it ... that these p63 deficient mice were aging prematurely," says Alea ...
... Genome Research Institute (NHGRI), one of the National Institutes ... Research Network will target 13 more organisms as part ... will expand biological knowledge and improve human health. , ... which is a federally chartered committee that advises NHGRI ...
... Skeletal muscles naturally repair themselves very efficiently after ... following damage from overuse during exercise, surgery or ... muscle repair slows noticeably, and in Duchenne Muscular ... functions can't cope with disease progression. , Researchers ...
Cached Biology News:Gene loss accelerates aging 2Possible treatment found for 'chemobrain' 2Possible treatment found for 'chemobrain' 3Possible treatment found for 'chemobrain' 4Possible treatment found for 'chemobrain' 5Muscle repair: Making a good system better, faster; implications for aging, disease 2Muscle repair: Making a good system better, faster; implications for aging, disease 3Muscle repair: Making a good system better, faster; implications for aging, disease 4
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Rice microRNA Microarray ...
... FP-6500 is the research-grade spectrofluorometer with a ... sensitivity S/N ratio 200 or greater for ... is especially designed to keep in mind ... as kinetics, stopped-flow, titration, or anisotropic measurements. ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known fish ...
... designed for genome-wide microRNA expression profiling ... powerful Paraflo microfluidic on-chip synthesis platform. ... of our comprehensive microRNA Expression Profiling ... The Viruses microRNA Microarray contains all ...
Biology Products: